| Revenue growth | 2% YoY in Q4; 3% YoY for FY26. |
|---|---|
| Margins | Operating EBITDA margin compressed to 25% for FY26 from 29% in FY25. |
| Demand visibility | Strong; ~400 active clients, 16 of top 20 pharma companies. |
| Management confidence | High; expanding leadership team and multi-modal facilities. |
Growth
Q4 FY26 Revenue grew 2% YoY; PAT before exceptional items fell 16% YoY. Full year FY26 Revenue grew 3% YoY.
Outlook
Investments in peptides, ADCs, and Biologics; infrastructure expansion in Bangalore, Hyderabad, and Baltimore site acquisition.
Risks
PAT decline due to lower margins (29% vs 34% in Q4 FY25) and foreign exchange volatility.
Earnings Call filed with BSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹446.10
- Market cap
- ₹18,008 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 96.8×Sector 43.8×
- Promoter holding
- 52.59%+0.00% QoQ
- FII holding
- 10.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Earnings Call Transcript: Key Takeaways
Syngene reports a transitional quarter with sequential recovery but YoY declines due to the absence of the large Librela revenue stream.
Syngene International Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 833 Cr (down 9% YoY, up 13% QoQ). Operating EBITDA margin 18% on forex hedge losses. PAT before exceptionals Rs 38 Cr (down 44% YoY). Focus on integrated CRDMO and first Bayview biologics deal.
Syngene International Results Update
Syngene reported Q2 FY27 revenue of Rs 833 Crore, up 13% sequentially, with PAT of Rs 32 Crore. Release includes P&L highlights and business updates.
Syngene International Management Change
Syngene reports changes in senior management: two heads move from SMP to Non-SMP, Ajay Tandon resigns effective October 30, 2026, and CFO Deepak Jain plans to leave. The CFO is a KMP, so this is a material leadership change.
Syngene International Q2 FY27 Results: Net Profit ₹32.2 Cr, Down 52.0% YoY
Syngene International Ltd reported revenue from operations of ₹832.7 Cr (-8.6% YoY) and net profit of ₹32.2 Cr (-52.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹32.2 Cr · -52.0% YoY
Syngene International Other Announcement
Syngene International Limited has submitted the quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.